The short version of c-Met signaling fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-09. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Hydrazine reflux is commonly used for reducing SLGO to SLG(R), but titrations show that only around 20–30% of the carboxylic groups are lost, leaving a significant number available for chemical attachment. Analysis of SLG(R) generated by this route reveals that the system is unstable and using a room temperature stirring with hydrochloric acid (< 1.0 M) leads to around 60% loss of COOH functionality. Room temperature treatment of SLGO with carbodiimides leads to the collapse of the individual sheets into star-like clusters that exhibited poor subsequent reactivity with amines (c. 3–5% conversion of the intermediate to the final amide). It is apparent that conventional chemical treatment of carboxylic groups on SLGO generates morphological changes of individual sheets that leads to a reduction in chemical reactivity, which may potentially limit their use in composite synthesis. Therefore, chemical reaction types have been explored. SLGO has also been grafted with polyallylamine, cross-linked through epoxy groups. When filtered into graphene oxide paper, these composites exhibit increased stiffness and strength relative to unmodified graphene oxide paper. Full hydrogenation from both sides of the graphene sheet results in Graphane, but partial hydrogenation leads to hydrogenated graphene. Similarly, both-side fluorination of graphene (or chemical and mechanical exfoliation of graphite fluoride) leads to fluorographene (graphene fluoride), while partial fluorination (generally halogenation) provides fluorinated (halogenated) graphene.
== Career == In 1969, Wittliff was recruited to the Department of Biochemistry at the University of Rochester School of Medicine as an assistant professor to work with Thomas C. Hall, a co-founder of the sub-specialty of medical oncology, to develop the new Cancer Center. In 1975, Wittliff was promoted to Associate Professor of Biochemistry and Head on the Section on Endocrine Biochemistry in the Cancer Center. In 1976, the University of Louisville School of Medicine and Dentistry recruited Wittliff as Chairman of the Department of Biochemistry, a position he would hold until 1983. He was also actively involved in the development of the first Cancer Center there. Although Wittliff began developing assays for breast cancer that quantified estrogen and progestin receptor proteins using radio-labeled steroid ligands while at Rochester, it was in Louisville that he collaborated with New England Nuclear (NEN, later NEN/DuPont) to develop the first FDA-Approved Assay Kits for quantifying these clinically relevant biomarkers Upon arrival at the University of Louisville, Wittliff also established a clinical laboratory certified by the Commonwealth of Kentucky and CLIA to provide clinically relevant assays that quantified levels of estrogen and progestin receptor proteins for breast cancer management. This led Wittliff and his group to develop reference materials for these protein biomarkers and establishment of inter-laboratory Quality Assurance Programs for standardizing determinations of estrogen and progestin receptor proteins in breast cancer biopsies.
== Australian and New Zealand Society for Mass Spectrometry == The major awards from the Australian and New Zealand Society for Mass Spectrometry (ANZSMS) are the ANZSMS Medal, Morrison Medal, Bowel Medal, Michael Guilhaus Research Award and ANZSMS Fellows.
Sources: en.wikipedia.org
== Career == Zaffaroni joined Syntex, then a small chemical company in Mexico, as a biochemist in 1951. He participated in turning Syntex into a major multinational pharmaceutical company, moving it to Palo Alto, California. He was appointed president of the U.S. subsidiary in 1962. In 1968, he founded ALZA, a syllabic abbreviation of his name, to develop medical treatments through controlled drug delivery. He modeled new delivery systems after the processes discovered in endocrinology – where glands deliver very small amounts of hormones but have a tremendous effect –. ALZA's first controlled drug delivery product was used to treat glaucoma. Other products that incorporated Zaffaroni's drug delivery technologies include Glucotrol, for non insulin-dependent diabetes; Duragesic, for management of severe chronic pain; NicoDerm CQ, for smoking cessation; and Transderm-Scop, to prevent nausea and vomiting associated with motion sickness. In 1980, Zaffaroni established DNAX, a developer of macromolecular products that combines the technologies of genetic engineering and immunobiology. In 1988 he co-founded Affymax, specializing in combinatorial chemistry to reduce the cost and time of identifying new medicines. In 1991 he co-founded Affymetrix, specializing in using genetics for developing new medicine. He was also involved in the creation of Perlegen Sciences, an Affymetrix spin-off which works on finding genetic causes of disease. In 1994, he founded Symyx Technologies, a company dedicated to utilizing combinatorial chemistry technologies.
An embalmer is someone who has been trained and qualified in the art and science of sanitization, presentation, and preservation of the human deceased. The term mortician is far more generic; it may refer to someone who is a funeral director, an embalmer, or just a person who prepares the deceased, with or without the formal qualification of an embalmer. Thus while all embalmers are morticians, many morticians are not embalmers and the terms are not intrinsically synonymous. Embalming training commonly involves formal study in anatomy, thanatology, chemistry, and specific embalming theory (to widely varied levels depending on the region of the world one lives in) combined with practical instruction in a mortuary with a resultant formal qualification granted after the passing of a final practical examination and acceptance into a recognized society of professional embalmers. The roles of a funeral director and embalmer are different, depending on local customs and the licensing body of the region in which they both operate. A funeral director arranges for the final disposition of the deceased, and may or may not prepare the deceased (by embalming, preparing for viewing or other legal requirements). Legal requirements over who can practice vary geographically. Some regions or countries do not have specific requirements, while others have clear prohibitions. In the United States, the title of an embalmer is largely based on the state in which they are licensed.
Shānghán Zábìng Lùn (傷寒雜病論), or The Treatise on Cold Damage and Miscellaneous Diseases, is the first Chinese monograph on diseases by Zhang Zhongjing. The original work is lost, but most of its contents are preserved in two extant works called Shānghán Lùn (傷寒論; "The Treatise on Cold Damage") and Jīnguì Yàolüè (金匱要略; "Essential Prescriptions from the Golden Chamber"). The first work primarily addresses externally triggered conditions while the latter work describes internally generated conditions. Zhang's specialized chapter on xiāo kě is found in Shānghán Lùn and Jīnguì Yàolüè. Nine subsections and nine formulae (herbal remedies) on wasting-thirst were recorded. The text proposed a theory of "three wasting-thirsts": upper- (associated with the lungs), middle- (associated with the stomach), and lower- (associated with the kidneys), all three of which shared excessive urine and thirst as symptoms. This theory was later expanded through the works of Liu Wansu (1120–1200 AD) and Wang Kentang (1549–1613 AD). According to Liu, "lower wasting-thirst" attributed to "kidney-yin deficiency" was associated with sweet urine (glycosuria). This may indicate differentiation akin to modern-day differentiation of diabetes mellitus and diabetes insipidus.
=== Intracellular transport === Little is known about intracellular kinetics of thyroid hormones. However, recently it could be demonstrated that the crystallin CRYM binds 3,5,3′-triiodothyronine in vivo.
Sources: en.wikipedia.org
DiCostanza relates the story that a customer came into the family deli and through an exchange matching the customer's requests and the deli's offerings, the hoagie was created. Additional spellings include "hoagy". Today, the hoagie is a common menu item in Philadelphia delis. Eateries such as Campo's, Geno's Steaks, and Pat's King of Steaks all offer hoagies on their menu. Woolworth's to-go sandwich was called a hoagie in all of its U.S. stores. Bánh mì sandwiches are sometimes referred to as "Vietnamese hoagies" in Philadelphia.
=== Demographics === One study conducted by investigators at the University of North Carolina Chapel Hill looked into donated sperm utilization within the United States from 1995 to 2017. Cross-sectional studies recorded that an estimated 170,701 individuals during 1995 used donated sperm, while the 2011 to 2013 cohort had a decreased amount of donated sperm use of 37,385. Most recently, in the 2015 to 2017 cohort, 440,986 individuals were reported to use donated sperm. When looking at 200,197 individuals across 2011–2017, 76% had a 4-year college degree or further while 24% had high school or 2-year college degree. In terms of household percent of poverty, 71% of the sperm bank users were at or above 400% of the household poverty level while only 11% were between 200 and 399% of the household poverty levels. Although the household income levels were not explicit, there seems to be an obvious trend that higher education level attainment (such as finishing college or higher) and being at much higher income level above the household poverty levels were the common tendencies in the sperm bank users.
==== MeSH D08.244.286 – cytochrome c group ==== MeSH D08.244.286.100 – cytochromes c MeSH D08.244.286.150 – cytochromes c' MeSH D08.244.286.200 – cytochromes c1 MeSH D08.244.286.300 – cytochromes c2 MeSH D08.244.286.600 – cytochromes c6
Serine–tRNA ligase, cytoplasmic, also called seryl-tRNA synthetase 1 is an enzyme that in humans is encoded by the gene SARS1 (previously SARS). SARS belongs to the class II amino-acyl tRNA family and is found in all humans, and functions as a serine–tRNA ligase which is involved in protein translation and is related to several bacterial and yeast counterparts.
=== Lobbying the FDA === In 2011, the FDA made it a priority to clarify the requirements for approval for such a closed-loop monitoring and drug delivery device for T1D, and announced it was preparing draft guidelines. Breakthrough T1D launched a campaign to influence those guidelines to be lenient. After the first closed-loop device was approved in 2016, Breakthrough T1D lobbied insurance companies to cover it. The campaign also put resources into educating people with diabetes on how to navigate health insurance in the United States, and into lobbying Congress to continue funding diabetes research through the NIH. The FDA lobbying campaign was part of a gradual realignment of the organization to focus on issues other than helping find a cure for type 1 diabetes, but to help treat and manage the disease. This broadened scope meant that the organization increasingly directed its funds to education and advocacy, along with research funding. This included lobbying insurance companies to pay for CGM devices, educating patients on how to advocate for themselves, and lobbying Congress for more NIH funding.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.